Aravive, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2018-12-11: Form 8-K; Period of report 2018-12-11; Description 8.01 Other Events; Details 8.01.
- 2018-12-05: Form 8-K; Period of report 2018-11-29; Description 4.01 Changes in Registrant's Certifying Accountant; Details 4.01.
- 2018-11-20: Form 8-K; Period of report 2018-11-15; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2018-11-13: Form 8-K; Period of report 2018-11-13; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2018-12-11 | 8-K | 2018-12-11 | 8.01 Other Events | 8.01 On December 11, 2018, Aravive, Inc. (the “Company”) issued a press release announcing that the Company has begun treating patients in the Phase 1b portion of a Phase 1b/Phase 2 trial combining AVB-S6-500 with standard-of-care therapies in patients with platinum-resistant recurrent ovarian cancer. | vsar-8k_20181211.htm |
| 2018-12-05 | 8-K | 2018-11-29 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On November 29, 2018, the Audit Committee of the Board of Directors of Aravive, Inc. (formerly known as Versartis, Inc.) (the “Company”) dismissed PricewaterhouseCoopers LLP (“PwC”) as its independent registered public accounting firm. | vsar-8k_20181129.htm |
| 2018-11-20 | 8-K | 2018-11-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 As previously reported by Aravive, Inc. (the “Company”) in its Current Report on Form 8-K dated October 12, 2018, effective October 12, 2018 (the effective date of the merger between Aravive Biologics, Inc., now a wholly owned subsidiary of the Company and Velo Merger Sub), Paul Westberg and Tracy M. Woody ceased to serve as Chief Business Officer and Chief Commercial Officer, respectively, of the Company; however, each continued as employees of the Company through November 9, 2018 to assist with transition matters. | vsar-8k_20181115.htm |
| 2018-11-13 | 8-K | 2018-11-13 | 8.01 Other Events | 8.01 On November 13, 2018, Aravive, Inc., a Delaware corporation (the “Company”), issued a press release announcing detailed results of its first-in-human Phase 1 clinical trial of AVB-S6-500 in healthy volunteers. | vsar-8k_20181113.htm |
| 2018-11-06 | 8-K | 2018-11-06 | 2.02 Results of Operations and Financial Condition | 2.02 On November 6, 2018, Aravive, Inc. (the “Company”) issued a press release announcing its financial results for the three- and- nine month periods ended September 30, 2018. | vsar-8k_20181106.htm |
| 2018-10-30 | 8-K | 2018-10-30 | 7.01 Regulation FD Disclosure | 7.01 Aravive, Inc. (the “Company”) prepared the Aravive Corporate Presentation attached as Exhibit 99.1 to this Current Report on Form 8-K (the “Investor Presentation”), which will be presented by the Company’s management during investor meetings beginning on October 30, 2018. | d646009d8k.htm |
| 2018-10-16 | 8-K | 2018-10-12 | 2.01 Completion of Acquisition or Disposition of Assets; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 2.01 On October 12, 2018 (the “Closing Date”), pursuant to the terms of the Agreement and Plan of Merger and Reorganization, dated as of June 3, 2018 (the “Merger Agreement”), by and between Versartis, Inc., a Delaware corporation (“Versartis”), Velo Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Versartis (“Merger Sub”), and Aravive Biologics, Inc., a Delaware corporation (“Aravive”), Merger Sub was merged with and into Aravive (the “Merger”), with Aravive surviving the Merger as a wholly-owned subsidiary of Versartis. 5.02 The information disclosed under Item 2.01 is incorporated by reference herein. 5.03 The information disclosed under Item 2.01 is incorporated by reference herein. 8.01 Shares of Company Common Stock were previously listed on the Nasdaq Global Select Market under the symbol “VSAR.” Versartis filed with The Nasdaq Stock Market, LLC (“Nasdaq”) a notification form for the listing of additional shares with respect to the shares of Company Common Stock to be issued to the holders of Aravive capital stock in the Merger so that these shares are listed on Nasdaq. | d624473d8k.htm |
| 2018-10-05 | 8-K | 2018-10-05 | 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events | 5.07 On October 5, 2018, Versartis, Inc. (“Versartis” or the “Company”) held a Special Meeting of Stockholders at the Garden Court Hotel in Palo Alto, California (the “Special Meeting”). 8.01 The Company plans to issue a press release announcing the closing of the merger, which is anticipated in the next few days following satisfaction of remaining conditions to closing. | d636250d8k.htm |
| 2018-09-20 | 8-K | 2018-09-14 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d625276d8k.htm |
| 2018-08-08 | 8-K/A | 2018-08-07 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On August 7, 2018, Versartis, Inc. (the “Company”) issued a press release announcing its financial results for the three and six month periods ended June 30, 2018. | vsar-8ka_20180807.htm |
| 2018-08-07 | 8-K | 2018-08-07 | 2.02 Results of Operations and Financial Condition | 2.02 On August 7, 2018, Versartis, Inc. (the “Company”) issued a press release announcing its financial results for the three and six month periods ended June 30, 2018. | vsar-8k_20180726.htm |
| 2018-06-04 | 8-K | 2018-06-03 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d586213d8k.htm |
| 2018-05-08 | 8-K | 2018-05-03 | 2.05 Costs Associated with Exit or Disposal Activities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.05 In October 2017, the Board of Directors of the Company approved a plan of termination to eliminate a number of positions effective October 20, 2017 (the “Restructuring Plan”), as part of its commitment to reduce costs following the failure of the Phase 3 VELOCITY trial of somavaratan to reach its primary endpoint. 5.02 The disclosure set forth above under Item 2.05 is incorporated herein by reference. | vsar-8k_20180503.htm |
| 2018-05-08 | 8-K | 2018-05-08 | 2.02 Results of Operations and Financial Condition | 2.02 On May 8, 2018, Versartis, Inc. (the “Company”) issued a press release announcing its financial results for the three month period ended March 31, 2018. | vsar-8k_20180508.htm |
| 2018-03-05 | 8-K/A | 2018-03-01 | 2.02 Results of Operations and Financial Condition | 2.02 On March 1, 2018, Versartis, Inc. (the “Company”) issued a press release announcing its financial results for the three- and twelve-month periods ended December 31, 2017. | vsar-8ka_20180305.htm |
| 2018-03-01 | 8-K | 2018-03-01 | 2.02 Results of Operations and Financial Condition | 2.02 On March 1, 2018, Versartis, Inc. (the “Company”) issued a press release announcing its financial results for the three- and twelve-month periods ended December 31, 2017. | vsar-8k_20180301.htm |
| 2018-01-25 | 8-K | 2018-01-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 20, 2018, the Compensation Committee (the “Committee”) of Versartis, Inc. (the “Company”) approved a salary increase for Kevin Haas, the Company’s principal accounting officer, raising his base salary from $250,800 per year to $270,800 per year. | d470647d8k.htm |
| 2018-01-08 | 8-K | 2018-01-04 | 1.02 Termination of a Material Definitive Agreement | 1.02 On January 4, 2018, Versartis, Inc. (the “Company”) received notice from Teijin Limited (“Teijin”) that Teijin was, pursuant to the agreement’s terms, terminating the Exclusive License and Supply Agreement among the Company, Versartis GmbH, a subsidiary of the Company, and Teijin, dated August 5, 2016 (the “License Agreement”), effective as of January 31, 2018. | d481118d8k.htm |